
    
      PRIMARY OBJECTIVES:I. To establish whether 2 vaccine dose levels of modified vaccinia virus
      ankara vaccine expressing p53 (MVAp53) vaccines are safe and well tolerated in patients with
      p53 over-expressing solid tumor malignancy.

      SECONDARY OBJECTIVES:I. To provide preliminary evidence of enhanced cellular and humoral
      immunity to p53.

      OUTLINE:This is a phase I, dose-escalation trial of modified vaccinia virus ankara vaccine
      expressing p53 (MVAp53).Patients receive MVAp53 subcutaneously (SC) on days 0, 21, and 42 in
      the absence of unacceptable toxicity.

      After completion of study treatment, patients are followed up annually for 5 years.
    
  